title: Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy.
authors.forename: Laurence
authors.initials: L
authors.lastname: Gamelin
authors.forename: Michèle
authors.initials: M
authors.lastname: Boisdron-Celle
authors.forename: Alain
authors.initials: A
authors.lastname: Morel
authors.forename: Anne Lise
authors.initials: AL
authors.lastname: Poirier
authors.forename: Virginie
authors.initials: V
authors.lastname: Berger
authors.forename: Erick
authors.initials: E
authors.lastname: Gamelin
authors.forename: Christophe
authors.initials: C
authors.lastname: Tournigand
authors.forename: Aimery
authors.initials: A
authors.lastname: de Gramont
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D002118:Calcium / Q000008:administration & dosage*; D015179:Colorectal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D007262:Infusions, Intravenous; D008274:Magnesium / Q000008:administration & dosage*; D015337:Multicenter Studies as Topic; D020258:Neurotoxicity Syndromes / Q000209:etiology*; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D008274:Magnesium; D002118:Calcium